Search

Your search keyword '"Shimomura, Hideki"' showing total 8 results
Start Over Author "Shimomura, Hideki" Journal journal of cardiology
8 results on '"Shimomura, Hideki"'

1. Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases – INVITATION trial

Author

Fujisue, Koichiro, primary, Shirakawa, Takuhiro, additional, Nakamura, Shinichi, additional, Yamamoto, Nobuyasu, additional, Oshima, Shuichi, additional, Matsumura, Toshiyuki, additional, Tsunoda, Ryusuke, additional, Hirai, Nobutaka, additional, Tayama, Shinji, additional, Nakamura, Natsuki, additional, Hirose, Toyoki, additional, Maruyama, Hideki, additional, Fujimoto, Kazuteru, additional, Kajiwara, Ichiro, additional, Sakamoto, Tomohiro, additional, Nakao, Koichi, additional, Sakaino, Naritsugu, additional, Hokimoto, Seiji, additional, Nagayoshi, Yasuhiro, additional, Hokamaki, Jun, additional, Shimomura, Hideki, additional, Sakamoto, Kenji, additional, Yamamoto, Eiichiro, additional, Izumiya, Yasuhiro, additional, Kaikita, Koichi, additional, Ogawa, Hisao, additional, and Tsujita, Kenichi, additional

Published
2018
Full Text
View/download PDF

2. Clinical outcomes of percutaneous coronary intervention for acute coronary syndrome between hospitals with and without onsite cardiac surgery backup

Author

Akasaka, Tomonori, primary, Hokimoto, Seiji, additional, Sueta, Daisuke, additional, Tabata, Noriaki, additional, Oshima, Shuichi, additional, Nakao, Koichi, additional, Fujimoto, Kazuteru, additional, Miyao, Yuji, additional, Shimomura, Hideki, additional, Tsunoda, Ryusuke, additional, Hirose, Toyoki, additional, Kajiwara, Ichiro, additional, Matsumura, Toshiyuki, additional, Nakamura, Natsuki, additional, Yamamoto, Nobuyasu, additional, Koide, Shunichi, additional, Nakamura, Shinichi, additional, Morikami, Yasuhiro, additional, Sakaino, Naritsugu, additional, Kaikita, Koichi, additional, Nakamura, Sunao, additional, Matsui, Kunihiko, additional, and Ogawa, Hisao, additional

Published
2017
Full Text
View/download PDF

3. Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial

Author

Sakamoto, Tomohiro, primary, Ogawa, Hisao, additional, Nakao, Koichi, additional, Hokimoto, Seiji, additional, Tsujita, Kenichi, additional, Koide, Shunichi, additional, Yamamoto, Nobuyasu, additional, Shimomura, Hideki, additional, Matsumura, Toshiyuki, additional, Oshima, Shuichi, additional, Kikuta, Koichi, additional, Oka, Hideki, additional, Kimura, Kazuo, additional, and Matsui, Kunihiko, additional

Published
2016
Full Text
View/download PDF

4. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial

Author

Tsujita, Kenichi, primary, Sugiyama, Seigo, additional, Sumida, Hitoshi, additional, Shimomura, Hideki, additional, Yamashita, Takuro, additional, Yamanaga, Kenshi, additional, Komura, Naohiro, additional, Sakamoto, Kenji, additional, Ono, Takamichi, additional, Oka, Hideki, additional, Nakao, Koichi, additional, Nakamura, Sunao, additional, Ishihara, Masaharu, additional, Matsui, Kunihiko, additional, Sakaino, Naritsugu, additional, Nakamura, Natsuki, additional, Yamamoto, Nobuyasu, additional, Koide, Shunichi, additional, Matsumura, Toshiyuki, additional, Fujimoto, Kazuteru, additional, Tsunoda, Ryusuke, additional, Morikami, Yasuhiro, additional, Matsuyama, Koushi, additional, Oshima, Shuichi, additional, Kaikita, Koichi, additional, Hokimoto, Seiji, additional, and Ogawa, Hisao, additional

Published
2015
Full Text
View/download PDF

5. Serial intravascular ultrasound assessment of very late stent thrombosis after sirolimus-eluting stent placement

Author

Yamanaga, Kenshi, primary, Tsujita, Kenichi, additional, Shimomura, Hideki, additional, Nakamura, Yoshinori, additional, Ogura, Yuji, additional, Onoue, Yoshiro, additional, Chazono, Naomi, additional, Nagata, Takeshi, additional, Morisaki, Shogo, additional, Kudo, Takashi, additional, Yamada, Yoshihiro, additional, Komura, Naohiro, additional, Miyazaki, Takashi, additional, Akasaka, Tomonori, additional, Horio, Eiji, additional, Sato, Koji, additional, Arima, Yuichiro, additional, Kojima, Sunao, additional, Kaikita, Koichi, additional, Tayama, Shinji, additional, Hokimoto, Seiji, additional, and Ogawa, Hisao, additional

Published
2014
Full Text
View/download PDF

6. The effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction

Author

Nakamura, Yoshinori, primary, Yamada, Yoshihiro, additional, Shimomura, Hideki, additional, Nagayoshi, Yasuhiro, additional, Tsujita, Kenichi, additional, Yamashita, Takuro, additional, Fukuda, Masaya, additional, Ohba, Keisuke, additional, Nako, Hisato, additional, Ogura, Yuji, additional, Chitose, Tadasuke, additional, Yamaguchi, Munetaka, additional, Nagata, Takeshi, additional, Soejima, Hirofumi, additional, Kaikita, Koichi, additional, Sugiyama, Seigo, additional, and Ogawa, Hisao, additional

Published
2009
Full Text
View/download PDF

7. Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.

Author

Nakamura Y, Yamada Y, Shimomura H, Nagayoshi Y, Tsujita K, Yamashita T, Fukuda M, Ohba K, Nako H, Ogura Y, Chitose T, Yamaguchi M, Nagata T, Soejima H, Kaikita K, Sugiyama S, and Ogawa H

Subjects
Aged, Angioplasty, Balloon, Coronary, Antipyrine administration & dosage, Biomarkers blood, Chemokine CCL2 physiology, Edaravone, Female, Heart Failure prevention & control, Humans, Male, Middle Aged, Myocardial Infarction etiology, Myocardial Infarction physiopathology, Patient Readmission statistics & numerical data, Prognosis, Stroke Volume, Ventricular Function, Left, Antipyrine analogs & derivatives, Chemokine CCL2 blood, Free Radical Scavengers administration & dosage, Myocardial Infarction therapy, Myocardial Reperfusion Injury prevention & control
Abstract

Background: Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the pathogenesis of acute coronary syndrome. We have recently demonstrated that the administration of edaravone before reperfusion attenuated reperfusion injury in patients with acute myocardial infarction (AMI)., Methods: Plasma MCP-1 levels were measured in 45 consecutive patients with AMI (edaravone group, n=25; control group, n=20). In the edaravone group, 30 mg edaravone was intravenously infused just before reperfusion. Plasma samples were obtained before and at 24h, 3, 5, 7, and 14 days after reperfusion. Cardiovascular events were defined as cardiac death, subacute thrombosis, or fatal arrhythmia. Heart failure requiring rehospitalization was evaluated at 12 months after reperfusion., Results: Plasma MCP-1 levels were not different between the two groups before reperfusion. Compared with the placebo group, the edaravone group had statistically lower maximum creatine kinase-MB levels (218±31 IU/l versus 145±21 IU/l, p<0.05) and plasma MCP-1 levels on day 3 after reperfusion (873±118 pg/ml versus 516±66 pg/ml, p<0.05). Heart failure requiring rehospitalization occurred in four patients in the control group, but did not occur in the edaravone group (p<0.05). At 12 months after reperfusion, left ventricular ejection fraction was statistically higher in the edaravone group than in the control group (62±2% versus 54±3%, p<0.05)., Conclusion: Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure. Suppression of plasma MCP-1 level by edaravone might induce better prognosis for AMI patients.

Published
2009
Full Text
View/download PDF

8. Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis.

Author

Nishikawa H, Miura S, Shimomura H, Tsujita K, Okamura K, Zhang B, Iwata A, Shirai K, Matsuo K, Arai H, and Saku K

Subjects
Aged, Angina Pectoris therapy, Animals, Case-Control Studies, Drug Therapy, Combination, Female, Humans, Male, Mice, Middle Aged, Odds Ratio, Angiotensin Receptor Antagonists, Coronary Disease therapy, Coronary Restenosis prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Stents
Abstract

Objectives: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) enhances the inhibitory effects of angiotensin-receptor blocker (ARB) on vascular neointimal formation in mice. The present case-control study investigated the efficacy of combined treatment with statin and ARB for preventing restenosis in patients with coronary artery disease., Methods: We examined 210 patients with angina pectoris undergoing elective coronary stenting for de novo lesions of native coronary arteries. All enrolled patients received aspirin and ticlopidine. The subjects included patients who received no statin (control group, n = 137) or started statin treatment (statin group, n = 73) with or without ARB treatment after stenting., Results: The rate of restenosis at 6 months after stent implantation in the statin group (19%) was significantly lower than that in the control group (32%). The restenosis rate in self-expanding Radius stents. (23%) was significantly lower than that in balloon-expandable Velocity stents (42%) independent of statin treatment. Patients treated with statins and ARBs were least likely [odds ratio (95% confidence interval): 0.30 (0.12-0.74)] to develop coronary restenosis, as assessed by multiple logistic regression analysis., Conclusions: These findings indicate that combined treatment with statin and ARB after stenting is a useful strategy for the prevention of coronary restenosis.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results